Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
458
Start Date
2024-02-22
Completion Date
2028-06-30
Last Updated
2026-08-07
Healthy Volunteers
No
Conditions
Interventions
Ivosidenib
in arm 1
Venetoclax
in arms 2-5
Gilteritinib
in arm 2
Homoharringtonine
in arms 4 and 7
Cytarabine
in arms 3 and 7
Daunorubicin/ Idarubicin /Mitoxantrone
in arms 3 and 7
Azacitidine
in arms 1,2 , 5 and 8
Lisaftoclax
in arms 7 and 8
PI3K inhibitors, histone deacetylase inhibitors, selinexor, novel liposomal drugs, and others
in arm 6
Locations (1)
Blood Hospital
Tianjin, China